MaxCyte Inc
NASDAQ:MXCT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.385
5.375
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MXCT stock under the Base Case scenario is 3.48 USD. Compared to the current market price of 3.56 USD, MaxCyte Inc is Overvalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
MaxCyte Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MXCT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
MaxCyte Inc
Balance Sheet Decomposition
MaxCyte Inc
Current Assets | 172.9m |
Cash & Short-Term Investments | 153.8m |
Receivables | 4.6m |
Other Current Assets | 14.5m |
Non-Current Assets | 75.7m |
Long-Term Investments | 42.8m |
PP&E | 31.9m |
Other Non-Current Assets | 1.1m |
Current Liabilities | 17.6m |
Accounts Payable | 1.9m |
Accrued Liabilities | 9.1m |
Other Current Liabilities | 6.7m |
Non-Current Liabilities | 17.7m |
Other Non-Current Liabilities | 17.7m |
Earnings Waterfall
MaxCyte Inc
Revenue
|
45.6m
USD
|
Cost of Revenue
|
-6.4m
USD
|
Gross Profit
|
39.2m
USD
|
Operating Expenses
|
-85.6m
USD
|
Operating Income
|
-46.4m
USD
|
Other Expenses
|
10.7m
USD
|
Net Income
|
-35.7m
USD
|
Free Cash Flow Analysis
MaxCyte Inc
USD | |
Free Cash Flow | USD |
MXCT Profitability Score
Profitability Due Diligence
MaxCyte Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
MaxCyte Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
MXCT Solvency Score
Solvency Due Diligence
MaxCyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
MaxCyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MXCT Price Targets Summary
MaxCyte Inc
According to Wall Street analysts, the average 1-year price target for MXCT is 9.44 USD with a low forecast of 7.07 USD and a high forecast of 11.55 USD.
Dividends
Current shareholder yield for MXCT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
Contact
IPO
Employees
Officers
The intrinsic value of one MXCT stock under the Base Case scenario is 3.48 USD.
Compared to the current market price of 3.56 USD, MaxCyte Inc is Overvalued by 2%.